Inventor · disambiguated record
Daniel J. Buzard
Also filed as: BUZARD DANIEL J · BUZARD DANIEL JOHN
40 granted patents·17 pending applications·233 citations·filing 2005–2025
97Inventor score
Files withARENA PHARM INC18H LUNDBECK AS13JANSSEN PHARMACEUTICA NV11JONES ROBERT M4LUNDBECK LA JOLLA RESEARCH CENTER INC4
Top patents by PatentIndex Score
57 records- 0195US11149292B2Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereofARENA PHARM INC·Filed 2016·Granted Oct 19, 2021·8 cites·21 claims
- 0295US7253200B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Aug 7, 2007·24 cites·21 claims
- 0394US10570106B2MAGL inhibitorsLUNDBECK LA JOLLA RESEARCH CENTER INC·Filed 2019·Granted Feb 25, 2020·7 cites·20 claims
- 0494US10030020B2Spirocycle compounds and methods of making and using sameABIDE THERAPEUTICS INC·Filed 2017·Granted Jul 24, 2018·7 cites·19 claims
- 0594US8580841B2Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disordersJONES ROBERT M·Filed 2009·Granted Nov 12, 2013·21 cites·51 claims
- 0694US8415484B2Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disordersJONES ROBERT M·Filed 2009·Granted Apr 9, 2013·29 cites·48 claims
- 0793US11434222B2MAGL inhibitorsH LUNDBECK AS·Filed 2021·Granted Sep 6, 2022·2 cites·12 claims
- 0893US9447041B2Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereofARENA PHARM INC·Filed 2015·Granted Sep 20, 2016·12 cites·22 claims
- 0993US9126932B2Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disordersARENA PHARM INC·Filed 2013·Granted Sep 8, 2015·17 cites·61 claims
- 1093US7928131B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Apr 19, 2011·14 cites·40 claims
- 1192US9522133B2Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disordersARENA PHARM INC·Filed 2015·Granted Dec 20, 2016·9 cites·42 claims
- 1292US9175320B2Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereofARENA PHARM INC·Filed 2014·Granted Nov 3, 2015·15 cites·42 claims
- 1390US12378219B2Crystalline forms of a MAGL inhibitorH LUNDBECK AS·Filed 2023·Granted Aug 5, 2025·1 cites·9 claims
- 1490US11059822B2MAGL inhibitorsH LUNDBECK AS·Filed 2017·Granted Jul 13, 2021·4 cites·18 claims
- 1589US10781211B2Spirocycle compounds and methods of making and using sameLUNDBECK LA JOLLA RESEARCH CENTER INC·Filed 2017·Granted Sep 22, 2020·4 cites·16 claims
- 1689US10093635B2MAGL inhibitorsABIDE THERAPEUTICS INC·Filed 2017·Granted Oct 9, 2018·8 cites·18 claims
- 1789US9981930B1MAGL inhibitorsABIDE THERAPEUTICS INC·Filed 2017·Granted May 29, 2018·9 cites·20 claims
- 1889US2025074874A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2024·Application pending·0 cites
- 1988US11691975B2MAGL inhibitorsH LUNDBECK AS·Filed 2021·Granted Jul 4, 2023·1 cites·20 claims
- 2088US8853419B2Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereofMONTALBAN ANTONIO GARRIDO·Filed 2011·Granted Oct 7, 2014·17 cites·24 claims
- 2187US10899737B2Piperazine carbamates and methods of making and using sameLUNDBECK LA JOLLA RESEARCH CENTER INC·Filed 2017·Granted Jan 26, 2021·4 cites·10 claims
- 2285US11149037B2Pyrazole MAGL inhibitorsH LUNDBECK AS·Filed 2018·Granted Oct 19, 2021·3 cites·24 claims
- 2385US9108969B2Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disordersARENA PHARM INC·Filed 2013·Granted Aug 18, 2015·6 cites·33 claims
- 2484US11214557B2MAGL inhibitorsH LUNDBECK AS·Filed 2020·Granted Jan 4, 2022·1 cites·16 claims
- 2582US9085581B2Processes for the preparation of S1P1 receptor modulators and crystalline forms thereofJONES ROBERT M·Filed 2011·Granted Jul 21, 2015·6 cites·30 claims
- 2681US11332453B2MAGL inhibitorsH LUNDBECK AS·Filed 2019·Granted May 17, 2022·1 cites·19 claims
- 2781US2023257349A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2022·Application pending·0 cites
- 2877US7705143B2Benzoimidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2008·Granted Apr 27, 2010·1 cites·22 claims
- 2976US11674163B2Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereofARENA PHARM INC·Filed 2021·Granted Jun 13, 2023·0 cites·15 claims
- 3076US11161856B2Spirocycle compounds and methods of making and using sameH LUNDBECK AS·Filed 2018·Granted Nov 2, 2021·1 cites·15 claims
- 3176US7723527B2Benzoimidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2008·Granted May 25, 2010·1 cites·24 claims
- 3272US2020407316A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2020·Application pending·0 cites
- 3368US2025326737A1Crystalline forms of a magl inhibitorH LUNDBECK AS·Filed 2025·Application pending·0 cites
- 3467US2019135752A1SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2018·Application pending·0 cites
- 3567US2024277795A1Inhibitors of cysteine proteases and methods of use thereofPARDES BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3666US8039498B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Oct 18, 2011·0 cites·20 claims
- 3765US7956071B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Jun 7, 2011·0 cites·34 claims
- 3865US7956066B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Jun 7, 2011·0 cites·40 claims
- 3965US7956057B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Jun 7, 2011·0 cites·34 claims
- 4065US7951808B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted May 31, 2011·0 cites·40 claims
- 4165US2024018120A1Magl inhibitorsH LUNDBECK AS·Filed 2021·Application pending·0 cites
- 4262US2017217885A1SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSARENA PHARM INC·Filed 2016·Application pending·0 cites
- 4359US12152029B2Crystalline forms of a MAGL inhibitorH LUNDBECK AS·Filed 2022·Granted Nov 26, 2024·0 cites·25 claims
- 4458US8017600B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2010·Granted Sep 13, 2011·0 cites·32 claims
- 4558US8017639B2Imidazole compoundsJANSSEN PHARMACEUTICA NV·Filed 2010·Granted Sep 13, 2011·0 cites·34 claims
- 4652US12448363B2Kinase inhibitorsVIDYA THERAPEUTICS INC·Filed 2021·Granted Oct 21, 2025·0 cites·25 claims
- 4752US2021147367A1Crystalline forms of a magl inhibitorLUNDBECK LA JOLLA RESEARCH CENTER INC·Filed 2020·Application pending·0 cites
- 4850US2022213074A1Abhd12 inhibitors and methods of making and using sameH LUNDBECK AS·Filed 2020·Application pending·0 cites
- 4949US11142526B2Spirocycle compounds and methods of making and using sameH LUNDBECK AS·Filed 2018·Granted Oct 12, 2021·0 cites·16 claims
- 5049US2010292233A1Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonistsARENA PHARM INC·Filed 2009·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel J. Buzard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →